Contribution of the (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections

Journal of Clinical Microbiology

Volumn 46, Issue 3, 2008, Pages 1009-1013

  Persat, Florence ^a   Ranque, Stéphane ^b   Derouin, Francis ^c   Michel Nguyen, Annie ^b   Picot, Stéphane ^a   Sulahian, Annie ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Laboratoire de Parasitologie Mycologie   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; BETA 1,3 GLUCAN; BETA-1,3-D-GLUCAN; DIAGNOSTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD DONOR; CANDIDEMIA; CONTROLLED STUDY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGUS ISOLATION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEPSIS; ANALYTICAL EQUIPMENT; ASPERGILLOSIS; BLOOD; CANDIDIASIS; CLINICAL TRIAL; EVALUATION; FRANCE; FUNGEMIA; LABORATORY DIAGNOSIS; LUNG MYCOSIS; MULTICENTER STUDY; UNIVERSITY HOSPITAL;

PNEUMOCYSTIS JIROVECII;

ASPERGILLOSIS; BETA-GLUCANS; BLOOD DONORS; CANDIDIASIS; FALSE POSITIVE REACTIONS; FRANCE; FUNGEMIA; HOSPITALS, UNIVERSITY; HUMANS; LUNG DISEASES, FUNGAL; MYCOSES; PNEUMONIA, PNEUMOCYSTIS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 40749148102     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02091-07     Document Type: Article

References (31)

1. Ascioglu, S., J. H. Rex, B. De Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, J. P. Donnelly, J. E. Edwards, O. Lortholary, J. Maertens, J. F. Meis, T. F. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, T. J. Walsh, et al. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: an international consensus. Clin. Infect. Dis. 34:7-14.
2. Chamilos, G., and D. P. Kontoyiannis. 2006. Defining the diagnosis of invasive aspergillosis. Med. Mycol. 44:5163-5172.
3. Fujii, T., T. Nakamura, and A. Iwamoto. 2007. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J. Infect. Chemother. 13:1-7.
4. Hope, W. W., T. J. Walsh, and D. W. Denning. 2005. Laboratory diagnosis of invasive aspergillosis. Lancet Infect. Dis. 5:609-622.
5. Kami, M., Y. Tanaka, Y. Kanda, S. Ogawa, T. Masumoto, K. Ohtomo, T. Matsumura, T. Saito, U. Machida, T. Kashima, and H. Hrai. 2000. Computed tomographic scan of the chest, latex agglutination test, and plasma (1→3)-β-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Hepatologica 85:745-752.
6. Kawazu, M., Y. Kanda, Y. Nannya, K. Aoki, M. Kurokawa, S. Chiba, T. Motokura, H. Hirai, and S. Ogawa. 2004. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-β-D-glucan test in weekly screening for invasive aspergillosis in patients with haematological disorders. J. Clin. Microbiol. 42:2733-2741.
7. Kelaher, A. 2006. Two non-invasive diagnostic tools for invasive aspergillosis: (1-3)-β-D-glucan and the galactomannan assay. Clin. Lab. Sci. 19:222-224.
8. Maertens, J., K. Theunissen, E. Verbeken, K. Lagrou, J. Verhaegen, M. Boogaerts, and J. V. Eldere. 2004. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br. J. Haematol. 126: 852-860.
9. Maertens, J., D. Deeren, D. Dierickx, and K. Theunissen. 2006. Preemptive antifungal therapy: still a way to go. Curr. Opin. Infect. Dis. 19:551-556.
10. Maertens, J., K. Theunissen, T. Lodewyck, K. Lagrou, and J. Van Eldere. 2007. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 50(Suppl. 1):2-17.
11. Marr, K. A., M. Laverdiere, A. Gugal, and W. Leisenring. 2005. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis. 40:1762-1769.
12. Marty, F. M., S. Koo, J. Bryar, and L. R. Baden. 2006. (1→3)-β-D-Glucan assay positivity in oncologic patients with Pneumocystis carinii pneumonia. Poster 46th Intersci. Conf. Antimicrob. Agents Chemother., poster M-1606.
13. Marty, F. M., C. M. Lowry, S. J. Lempitski, D. W. Kubiak, M. A. Finkelman, and L. R. Baden. 2006. Reactivity of (1→3)-β- D-glucan assay with commonly used intravenous antimicrobials. Antimicrob. Agents Chemother. 50:3450-3453.
14. Miyazaki, T., S. Kohno, K. Mitsutake, S. Maesaki, I. Tanaka, N. Ishikawa, and K. Hara. 1995. Plasma (1,3)-β-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J. Clin. Microbiol. 33:3115-3118.
15. Obayashi, T., M. Yoshida, T. Mori, H. Goto, A. Yasuoka, H. Iwasaki, H. Teshima, S. Kohno, A. Horiuchi, A. Ito, H. Yamaguchi, K. Shimada, and T. Kawai. 1995. Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17-20.
16. Odabasi, Z., G. Mattiuzi, E. Estey, H. Kantaijian, F. Sacki, R. J. Ridge, P. A. Ketchum, M. A. Finkelman, J. H. Rex, and L. Ostrosky-Zeichner. 2004. β-D-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis. 39:199-205.
17. Okamoto, K., T. Yamamoto, D. Nonaka, H. Shin, K. Okada, J. Hayashi, and S. Kashiwagi. 1998. Plasma (1→3)-β-D-glucan measurement and polymerase chain reaction on sputum as practical parameters in Pneumocystis carinii pneumonia. Intern. Med. 37:618-621.
18. Ostrosky-Zeichner, L., B. D. Alexander, D. H. Kett, J. Vazquez, P. G. Pappas, F. Saeki, P. A. Ketchum, J. Wingard, R. Schiff, H. Tamura, M. A. Finkelman, and J. H. Rex. 2005. Multicenter clinical evaluation of the (1-3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41:654-659.
19. Pazos, C., J. Ponton, and A. Del Palacio. 2005. Contribution of (1→3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic patients: a comparison with serial screening for circulating galactomannan. J. Clin. Microbiol. 43:299-305.
20. Pazos, C., M. D. Moragues, G. Quindos, J. Ponton, and A. Del Palacio. 2006. Diagnostic potential of (1→3)-β-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev. Iberoam. Micol. 23:209-215.
21. Pfaller, M. A., and D. J. Dieckema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
22. Pfeiffer, C. D., J. P. Fine, and N. Safdar. 2006. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 42: 1417-1427.
23. Pickering, J. W., H. W. Sant, C. A. P. Bowles, W. L. Roberts, and G. L. Woods. 2005. Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J. Clin. Microbiol. 43:5957-5962.
24. Sendid, B., M. Tabouret, J. L. Poirot, D. Mathieu, J. Fruit, and D. Poulain. 1999. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J. Clin. Microbiol. 37:1510-1517.
25. Sendid, B., J. L. Poirot, M. Tabouret, A. Bonnin, D. Caillot, D. Camus, and D. Poulain. 2002. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J. Med. Microbiol. 51:433-442.
26. Shimizu, A., H. Oka, T. Matsuda, and S. Ozaki. 2005. (1→3)-β-D-Glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin. Exp. Rheumatol. 23:678-680.
27. Stynen, D., A. Goris, J. Sarfati, and J. P. Latgé. 1995. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J. Clin. Microbiol. 33:497-500.
28. Sulahian, A., S. Touratier, and P. P. Riband. 2003. False-positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N. Engl. J. Med. 349:2366-2367.
29. Takesue, Y., M. Kakehashi, H. Ohge, Y. Imamura, Y. Murakami, M. Sasaki, M. Morifuji, Y. Yokoyama, M. Kouyama, T. Yokoyama, and T. Sueda. 2004. Combined assessment of β-D-glucan and degree of Candida colonization before starting empiric therapy for candidiasis in surgical patients. World J. Surg. 28:625-630.
30. Teramoto, S., D. Sawaki, S. Okada, and Y. Ouchi. 2000. Markedly increased plasma (1→3)-β-D-glucan is a diagnostic and therapeutic indicator of Pneumocystis carinii pneumonia in a non-AIDS patient. J. Med. Microbiol. 49: 391-392.
31. Yasuoka, A., N. Tachikawa, K. Shimada, S. Kimura, and S. Oka. 1996. (1→3)β-D-Glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin. Diagn. Lab. Immunol. 3:197-199.